Benign Conditions

In this interview, Karl-Erik Andersson, MD, PhD, discusses current treatments for common voiding dysfunctions and future directions, including central nervous system agents and combination therapies.

Findings from preclinical studies evaluating the performance of an investigational single-use digital flexible ureteroscope (Lithovue, Boston Scientific) support it as a viable alternative to current non-disposable flexible digital and fiberoptic ureteroscopes, said Brian H. Eisner, MD, at the World Congress of Endourology and SWL in London.

Other pipeline products discussed in this article include agents for urinary catheter blockage, prostate cancer, bladder cancer, and overactive bladder.

The authors evaluated cumulative incidence of re-operation after various surgical procedures for urinary incontinence within 5 years.

A recent systematic review found that the total incidence of serious complications and/or sling failure with respect to incontinence was 15.3%.

A novel artificial urinary sphincter is safe and effective in men with stress urinary incontinence, according to data from a small study presented at the International Continence Society annual meeting in Montreal.

The Adjustable Transobturator Male System addresses one of the challenges with slings.

Novel ultrasound-based techniques for propelling and breaking kidney stones could soon join ESWL and URS in the urologist’s treatment armamentarium. In this interview, Michael Bailey, PhD, discusses how these technologies work, what they’re capable of, and where they are in development.

A robot-assisted abdominal approach to pelvic organ prolapse repair has a favorable safety profile and is associated with durable anatomic outcomes, findings of a retrospective chart review indicate.

Other products highlighted in this slideshow include a trial system for incontinence therapy, a compact catheter, a wearable digital technology solution for continence care assessment and management, and laser fiber and sheath system.

A prostate cancer vaccine and an infertility diagnostic tool are among the other pipeline products discussed in this round-up.

OnabotulinumtoxinA (Botox) appears to offer long-term benefits in patients with neurogenic detrusor overactivity, recent study results indicate.

Symptomatic urinary tract infection is unlikely after office-based cystoscopy, although recent antibiotic exposure or hospitalization raise infection risk, according to a recent study.

A recent study evaluated electrical stimulation of the afferent nerves in the foot as a way of decreasing symptoms of overactive bladder.

Researchers recently presented 12-month follow-up data from a prospective, multicenter trial of a device for sacral neuromodulation.

Brian Howard Eisner, MD, examined antibiotic use in ureteroscopy and PCNL in two studies presented at the AUA annual meeting in New Orleans. He discusses the studies’ findings with Urology Times.

Researchers compared artery thickness in children with and without kidney stones.

A new study on the use of a reflux calculator, developed at Children’s Hospital of Orange County in Irvine, CA, suggests the web-based risk stratification and probability model helps to predict vesicoureteral reflux patients’ 2-year risk of breakthrough urinary tract infection.

One in 30 women treated for stress urinary incontinence with synthetic mesh slings might require mesh removal or revision 10 years post-SUI mesh surgery.

A novel treatment for the targeted removal of prostate tissue may soon be coming to a hospital near you. According to the results of a phase II study presented at the AUA annual meeting in New Orleans, Aquablation, a minimally invasive water ablation therapy, demonstrated efficient and precise resection of prostate tissue in patients with BPH.

The prostatic urethral lift (PUL [UroLift, NeoTract, Inc.]) yields successful 3-year durability and superior rate of improvement of BPH symptoms compared to transurethral resection of the prostate, according to separate studies presented at the AUA annual meeting in New Orleans.

In this round-up of new urology products and services, learn about the FDA approving an oral agent for HSDD, an app that helps men with erectile dysfunction, and more.

In this installment of "Product Preview," also look for information on products in the pipeline for renal cell carcinoma and interstitial cystitis.

The management of BPH has had an interesting roller coaster ride over the past 25 years with new medicines, minimally invasive surgical therapies, and a host of novel surgical technologies, including lasers and bipolar electrosurgery.

A handheld transurethral therapy that delivers targeted sterile water vapor reduces lower urinary tract symptom severity in patients with BPH with no impact on sexual function.